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Abstract 
Background 
Anxiety is common and problematic in dementia, yet there lacks effective treatments.  
Aims 
To develop a CBT manual for anxiety in dementia, and determine its feasibility 
through an RCT. 
Methods  
A ten session CBT manual was developed following literature search, expert 
consultation, consensus conference and field testing. Fifty participants with dementia 
and anxiety (and their carer) were randomly allocated to CBT plus treatment as usual 
(TAU) (n=25) or TAU (n=25). Outcome and cost measures were administered at 
baseline, 15 weeks and 6 months.  
Results 
At 15 weeks, there was an adjusted difference in anxiety (using the RAID) of (-3.10; 
95% CI -6.55, 0.34) for CBT compared to TAU, which fell short of statistical 
significance. There were significant improvements in depression at 15 weeks after 
adjustment (-5.37; 95% CI - 9.50, -1.25). Improvements remained significant at six 
months. CBT was cost neutral. 
Conclusions 
CBT was feasible (in terms of recruitment, acceptability and attrition) and effective. A 
fully powered RCT is now required. 
Declaration of Interest 
None 
 
 
Introduction 
Anxiety in dementia is common, with prevalence estimated from 5-21% for anxiety 
disorders and up to 71% for anxiety symptoms [1]. Anxiety may physically present as 
motor restlessness, agitation, day/night disturbance and/or aggression, and as the 
dementia progresses, often results in exacerbated symptoms due to increased 
dependency and behavioural problems [2,3]. Anxiety in dementia often receives little 
attention [1]. People may get treated with psychotropic medication (such as 
antidepressants), even though there is little if any evidence of benefit and use of 
antipsychotics presents serious risks [4]. Cognitive behaviour therapy (CBT) [5] is a 
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collaborative psychological approach that addresses the interaction between people’s 
thoughts, feelings and behaviour. There is robust evidence that CBT is an effective 
first-line strategy for anxiety in older people without dementia [6]. The UK National 
Health Service widely endorses CBT through its “Improving Access to Psychological 
Therapies” (IAPT) programme [7], which supports primary care trusts in 
implementing CBT for depression and anxiety. There is evidence that people with 
dementia can learn and develop skills [8], which suggests that CBT could be used for 
people with dementia, as it has been in other impaired populations including learning 
disabilities [9]. There is some evidence for the feasibility of CBT for anxiety and 
depression in dementia, primarily through case studies and two small RCTs in the US 
[e.g. 2, 10, 11, 12]. They all concluded that larger trials are needed. This study had 
two phases, which correspond to phase I and II of the MRC’s guidelines for 
developing a complex intervention and assessing feasibility [13]. They were: 
(1) To develop a CBT intervention manual.  
(2) To assess the feasibility of the intervention through a single-blind, pilot RCT of 
CBT plus treatment as usual (TAU) versus TAU for people with dementia (supported 
by their carers). This  included an assessment of acceptability, compliance, 
recruitment, retention and costs. 
 
Method 
 
Ethics statement  
Ethical approval was obtained through the ‘East London 3 Research Ethics 
Committee’ (reference number 10/H0701/124). 
 
Stage I: Manual development 
The manual was developed in several stages, described previously [14]. Its 
development involved systematic literature review, expert review, a consensus 
conference with 30 people and field-testing with three people with dementia. The 
version used in this trial involved a three-phase formulation-driven therapy based on 
Beck and Clark’s [5] cognitive model of anxiety, whereby an individualised (person-
centred) formulation is collaboratively reached to guide progress. Phase 1 involves 
building a collaborative relationship, psychoeducation about CBT and the excess 
disability caused by anxiety in dementia, self-monitoring, developing an 
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individualised formulation and identifying goals. During this first phase, the level of 
carer involvement is also established. The carer’s role is to support the person with 
dementia in implementing strategies, for example applying what has been discussed 
during sessions in everyday life. Their involvement could range from very little (e.g. 
attending brief parts of some sessions) to being present at all times. Phase 2 involves 
the application of change processes, which the therapist can adapt according to the 
needs and strengths of the individual. These include identifying and practicing 
strategies for feeling safe, identifying and challenging unhelpful cognitions, 
addressing ‘realistic negative automatic thoughts’, calming thoughts (on cue cards) 
and behavioural experiments. Phase 2 also had optional ‘modules’ for considering 
longstanding unhelpful ‘rules for living’ and for addressing interpersonal difficulties 
between the carer and person with dementia. Phase 3 works on ending the therapy and 
developing a blueprint for the future. This includes reviewing and consolidating 
learned skills, integration of skills into everyday life and considering the future 
involvement of carers and others.  
 
Stage II: Randomised Controlled Trial 
Design 
A single-blind, multicentre, pilot randomised controlled trial of CBT plus treatment as 
usual (TAU) versus TAU for people with anxiety and dementia. As no trials have 
been done in this area, we were unable to estimate the likely effect size of this 
intervention. The sample size was chosen on pragmatic grounds as sufficient to 
demonstrate adequate recruitment and retention, although 50 participants would be 
sufficient to detect an effect size of 0.8 with 80% power and 5% significance. We also 
aimed to provide data on the possible effect size of the intervention in order to inform 
a power analysis for a large scale RCT.  
 
Participants 
Participants were eligible for inclusion if they (1) Met DSM-IV criteria for dementia 
in the mild-to-moderate range, determined by a Clinical Dementia Rating (CDR) [15] 
score of 0.5, 1 or 2; (2) Had clinical anxiety, as determined by a score of 11 or above 
on the Rating Anxiety in Dementia scale (RAID) [16], with or without co-morbid 
depression; (3) Lived in the community; (4) Had a self-identified carer who was 
willing to participate in the therapy; (5) Were able to understand and communicate in 
5 
 
English; (6) Were willing to engage in therapy involving discussion of thoughts and 
feelings. 
 
Participants were excluded if they had (1) A co-morbid psychiatric disorder (e.g. 
psychosis) or challenging behaviour (e.g. severe agitation), likely to prevent 
engagement in therapy or (2) The presence of a congenital learning disability or 
severe physical illness, which could impact on participation. 
 
Procedure 
Potential participants were primarily identified through NHS secondary care services 
within two NHS trusts. People who appeared to meet inclusion criteria were contacted 
by telephone or in writing by the referrer. If they chose to participate, informed 
consent was sought from participants and their carers using current guidance from the 
British Psychological Society on evaluation of capacity. Following this, people were 
screened for suitability and the full assessment was conducted if they were deemed 
suitable.  
 
Assessments 
All assessments were administered by the research assistant at week 1 (baseline), 
week 15 (follow-up 1) and 6 months (follow-up 2). Initial field testing of the 
intervention revealed that it took more than ten weeks to complete the ten sessions, 
due to factors such as illness and holidays. Follow-up 1 therefore took place at 15 
weeks, to increase the likelihood that the intervention had been completed. Baseline 
data collected included age, gender, ethnic group, use of medication and participation 
in other activities.  
 
The primary outcome was measured using the Rating for Anxiety in Dementia 
(RAID) [16]. This rates signs and symptoms of anxiety using interviews with carers 
and people with dementia. There are 18 questions in four categories: worry, 
apprehension, vigilance, motor tension and autonomic hypersensitivity. A score of 11 
or above indicates significant clinical anxiety, with a maximum possible score of 54. 
It has good inter-rater and test-retest reliability and is sensitive to change. 
 
Costs were measured using the Clinical Services Receipt Inventory (CSRI) [17], 
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which collects information about the participant’s receipt of health and social care 
services, equipment or adaptations, medication, accommodation (e.g. care home), 
income and benefits. Changes in the receipt of these services can be tracked over 
time, as it asks for service receipt over the previous three months each time it is 
administered.   
 
Depression was measured using the Cornell Scale for Depression in Dementia 
[CSDD, 18]. This rates depression in the person with dementia in five domains 
including mood-related signs, behavioural disturbance and ideational disturbance, 
using interviews with people with dementia and proxies. Good reliability and validity 
have been demonstrated. The mood of both the person with dementia and their carer 
was also measured using the Hospital Anxiety and Depression Scale (HADS) [19], a 
widely used measure validated for all age groups. Quality of life was measured using 
the Quality of Life-Alzheimer’s Disease (QOL-AD) [20], a self-report measure for the 
person with dementia and their carer, with 13 items covering domains including 
physical health, energy, friends and fun. It has excellent inter-rater reliability and 
internal consistency, and good content, criterion and construct validity. Behavioural 
disturbance was measured by the Neuropsychiatric Inventory (NPI) [21]. This 
assesses ten areas including delusions, hallucinations, dysphoria and 
agitation/aggression. Content and concurrent validity, inter-rater and test-retest 
reliability and internal consistency are all good. Cognitive function was assessed by 
the Mini-Mental State Examination (MMSE) [22]. This is an internationally 
recognised, 11-item set of simple tasks presented to the participant including 
orientation to time and place, attention, recall, language and visual construction. It has 
a maximum score of 30 points, with 24 or less suggesting cognitive impairment. 
Reliability and validity are satisfactory. Person-carer relationship was assessed using 
the Quality of Caregiver and Patient Relationship (QCPR) [23]. This is a 14-item 
scale measuring relationship quality including the level of criticism and level of 
warmth, rated by both the person and their carer. Good reliability and validity have 
been demonstrated. 
 
Randomisation procedures  
Patient-carer dyads were randomly allocated to either CBT or TAU, with an 
allocation ratio of 1:1. The randomisation sequence was generated using Stata by an 
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independent statistician and administered by PRIMENT Clinical Trials Unit after the 
participant/carer had provided consent and baseline data. A method of blocking was 
employed (with block sizes varying between 4 and 6) to help ensure equal numbers in 
the intervention and control arms. Once each individual was randomised, the Clinical 
Trials Unit informed the trial psychologist of allocation and the psychologist then 
informed the individual by telephone. Assessors were blinded to group allocation. 
Participants with dementia and their carers could not be blinded to group allocation, 
due to the intervention being psychosocial. However, they were reminded not to 
disclose which arm of the study they were assigned to at the beginning of each 
assessment, in an attempt to minimise detection bias. 
 
Intervention and control conditions  
CBT plus TAU: The patient-carer dyads participated in up to ten weekly sessions, 
each lasting approximately one hour. This number was determined on the basis of the 
published literature, the team’s experience and patient and carer feedback during field 
testing. Sessions were shortened and breaks taken as required to maintain attention. 
Sessions were delivered by four Clinical Psychologists with experience of working 
with people with dementia. Participants receiving CBT were permitted to utilise any 
standard treatment available for anxiety if required. 
Treatment as usual (TAU): This was defined as the standard treatment available to 
people with anxiety and dementia, which was most likely to include medication or no 
treatment. 
 
Statistical methods 
Data were analysed using the intention to treat principle.  Baseline summary statistics 
by randomised group were calculated.  Outcomes at 15 weeks and six months were 
modelled separately using linear regression, with coefficients and 95% confidence 
intervals presented (see statistical appendix).  Results for the participants with 
dementia are presented unadjusted and adjusted for baseline anxiety (score on the 
RAID) and baseline cognition (score on the MMSE). The sample size meant that we 
were unable to adjust for any other baseline covariables. Analyses on the carer scales 
were adjusted for the value of the scale at baseline.  It was agreed a priori that the 
adjusted analysed would be the primary analyses.  All analyses were carried out using 
Stata version 12.1. 
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Cost analysis 
The cost analysis adopted a health and social care (HSC) perspective, which considers 
only costs incurred by organisations providing health and social care services. Unit 
costs were obtained from the PSSRU compendium for 2011 [24] where possible. It 
was decided a priori that cost differences at both follow-up points would be compared 
after adjusting for pre-baseline HSC costs, baseline MMSE score and baseline RAID 
score, using multiple regression. To minimise the effect of skewness, 95% bias-
corrected confidence intervals for between-group mean costs were estimated using 
non-parametric bootstrapping techniques (re-sampling with replacement; 1000 
repetitions). Missing values within the main cost analysis were addressed through 
imputing mean values. For each variable used in the cost analysis, missing values 
accounted for fewer than 15% of total responses. Two sensitivity analyses were 
conducted. The first used no imputations (costs that could not be calculated due to 
missing data were excluded) and the second excluded outliers (individuals with 
abnormally high costs in one or more cost categories- e.g. accommodation costs). 
  
Results 
Sample 
Tables 1 and 2 show the characteristics of the sample; table 1 for the people with 
dementia and table 2 for the carers. All participants had received a formal diagnosis of 
dementia. There were 20 males and 30 females aged between 63 and 98 years.  
Randomised groups were balanced in terms of gender, mean age and ethnicity of the 
patient (Table 1).  In the CBT plus TAU group, all carers were family members, 
whereas this was the case for 80% in the TAU group.  This might explain the much 
higher median hours spent a week caring in the CBT versus the TAU group (61 versus 
15), with family carers generally describing their care as 24/7 (Table 2). The median 
MMSE was 23 for both groups.  However, the median RAID was lower in the CBT 
plus TAU group compared to the TAU group (17; IQR 14, 21 versus 22; IQR 17, 24 
respectively) (Table 1). There was also a lower use of anxiolytic medication in the 
CBT plus TAU group (8%) compared to the TAU group (24%).  
 
[Table 1 here: Baseline summary statistics for the participant by randomised group] 
[Table 2 here: Baseline summary statistics for the carer by randomised group] 
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Treatment as usual 
All participants received standard treatment, described as TAU. 62% of the total 
sample was on antidepressant medication and 16% on anxiolytic medication. 30% 
were using day services. Use of both antidepressant and anxiolytic medication was 
higher in the TAU group. There was no evidence that anyone was taking part in any 
other therapeutic intervention specifically for anxiety. 
 
Recruitment and Retention 
Figure 1 shows the flow of participants through the trial. 153 participants were 
referred to the study, of which 93 came from secondary care services (Memory 
clinics, Admiral nursing), 26 through searches of case notes by the researcher, 22 
from voluntary services, 7 via other research studies and 5 via other routes (e.g. self-
referral). 103 dyads were screened out as they did not meet eligibility criteria (63), 
refused participation (34), person with dementia passed away (4) or became ill (2). 50 
participant carer dyads were randomised to either CBT plus TAU (n=25) or TAU only 
(n=25). Nine participants withdrew from the trial at first follow up. Two participants 
were unable to be assessed at first follow up but were assessed for second follow up. 
Another three withdrew from the trial at second follow up. Primary outcome data 
were available for all participants who were assessed at the first follow up. 
 
[Figure 1: Consort Diagram here] 
 
Feasibility  
It was possible to recruit the required number within the given timeframe (14 
months), with approximately one in three referrals recruited into the trial. Attrition 
was acceptable: 39 of the 50 dyads were retained at 15 weeks and 38 at 6 months. 
Generally, people took up the intervention when offered it. Of the 25 participants 
allocated to CBT plus TAU, four dropped out, three due to the person or carer 
withdrawing and one due to death. Of the remaining 21, 14 people attended all ten 
sessions. Seven people felt they had achieved their treatment goals sooner and 
finished early after six (n=2), seven (n=2), eight (n=2) and nine sessions (n=1). Of the 
25 allocated to TAU, eight dropped out of the research, four due to carer stressors, 
two due to dissatisfaction of allocation, one due to stress in the person with dementia 
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and one where contact was lost. There was a significant difference in gender between 
those who were retained and dropped out. Of those retained, 48% were male and of 
those who dropped out, 9% were male. A greater percentage of participants with 
moderate dementia dropped out (36%) compared with those retained in the study 
(10%). There were no reported adverse effects or side effects of the intervention. 
 
The trial therapists were asked to consider each person with dementia’s ‘suitability for 
cognitive therapy’. This provided a systematic approach to identifying those areas 
where ‘pre-therapy’ techniques may be required, for example strategies to expand 
emotional vocabulary or increase awareness of the link between cognitions, actions 
and emotions. Memory and language problems could be compensated for in most 
cases except where the degree of severity was such that the person with dementia was 
unable to ‘hold in mind’ the presence of the therapist during sessions and was 
continuously surprised by their presence, or in circumstances where the ability to have 
meaningful verbal exchanges was severely compromised.  The therapy was least 
feasible in cases where there were significant and longstanding interpersonal 
difficulties between the person with dementia and their family carer or where there 
was no consistent family carer and the person with dementia needed a high level of 
in-session support. 
 
Adherence 
All four CBT therapists received a two-hour training session on the manual by GC, a 
Clinical Psychologist with 15 years experience of using CBT for older people. The 
same psychologist also provided clinical supervision. Sessions were recorded where 
possible and one session per dyad was coded by an independent Psychologist for 
adherence to CBT using the Cognitive Therapy Scale - Revised (CTS-R) [24]. Six 
cases were excluded from rating due to requests not to be recorded (n=4), technical 
problems (n=1) and work primarily involving the carer (n=1). Of the 15 recordings 
rated, an average score in the “competent” range was achieved. There was a range in 
scores, largely due to the range of therapist expertise and extent to which participants 
met ‘suitability for Cognitive Therapy’ criteria. 
 
Main clinical outcome at 15 weeks 
Table 3 shows that, using RAID, anxiety was significantly lower in the CBT plus 
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TAU group at 15 weeks (-4.32; 95% CI -8.21, -0.43).  This lost statistical significance 
when adjusted for baseline anxiety and cognition (-3.10; 95% CI -6.55, 0.34).   
 
Secondary outcomes at 15 weeks 
Depression, as measured by the CSDD was also significantly lower in the CBT plus 
TAU group and remained following adjustment (-5.37; 95% CI -9.50, -1.25).  
However, we emphasise that because of the small sample we were not able to also 
adjust for baseline CSDD score in this analysis.  There were no significant differences 
or notable trends in quality of life, cognition, anxiety and depression (measured by the 
HADS) or the quality of caregiver patient relationship from the carer or patient 
perspective. 
 
[Table 3 here: Outcomes at 15 weeks and 6 months, coefficients for CBT] 
 
Longer term outcomes 
The advantage shown by the CBT plus TAU group over the TAU group with regard to 
anxiety was maintained at six months, with those in the CBT group scoring on 
average 4.59 points lower than the TAU group although this fell a little short of 
statistical significance after adjustment (95% CI-9.34, 0.15).  The difference in 
depression score on the CSDD was similar to that at 15 weeks and was also 
statistically significant after adjustment (-5.08; 95% CI -9.25, -0.92).  As at 15 weeks, 
there were no statistically significant differences in any other variables.  
 
Cost analysis 
Cost per session for the intervention was £114.36. This included the average time 
spent by the therapist administering the intervention (including planning), therapist 
training, travel and equipment. Average session attendance per person was 8.8, hence 
average total intervention cost per person was £1002. The CBT plus TAU group had 
higher pre-baseline mean total cost from a HSC perspective compared to TAU, with a 
mean difference of £834.27 (Table 4). Although this difference was not significant 
(with a 95% bias-corrected confidence interval of -£285.77, £3069.38), it needs to be 
taken into account when comparing post-randomisation costs, and was controlled for.  
 
Table 5 shows costs incurred between baseline and follow-up 1. While the costs (from 
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a HSC perspective) are significantly lower for the CBT plus TAU group (unadjusted 
mean difference -£680.04; adjusted mean difference -£564.38), this was not enough to 
offset the intervention cost. Including the cost of the intervention, total costs were 
higher for the CBT plus TAU group compared to TAU, although this difference was 
not significant, with an unadjusted mean difference of £321.97 (95% bias corrected  
confidence interval of  -£345.94, £946.85), and adjusted mean difference of 
£769.80(95% bias-corrected confidence interval of -£121.99, £1697.38).  
 
Between the first and second follow-up, mean costs were again higher for the CBT 
plus TAU group compared to TAU, although this difference was not significant, with 
an unadjusted mean difference of £1085.02, (95% bias-corrected confidence interval 
of -£354.81, £4078.64), and an adjusted mean difference of £256.12, (95% bias-
corrected confidence interval of -599.05, 1506.23) (Table 6). The first sensitivity 
analysis (which used no imputations) found no deviations from the main analysis with 
regards to trends or significance of any findings. The second sensitivity analysis 
(which removed high cost outliers) found no significant difference in costs from a 
HSC perspective at first follow-up, which was not surprising as sample size was 
reduced.  
 
[Table 4 here: Participant pre-baseline costs (£) by service group with mean 
imputations]  
[Table 5 here: Participant costs (£) between baseline and first follow-up (15 weeks) 
by service group with mean imputations]  
[Table 6 here: Participant costs (£) between first follow-up (15 weeks) and second 
follow-up (6 months) by service group with mean imputations] 
 
Power calculation for a full trial 
For an unadjusted analysis, to detect a difference of four points on the RAID at 15 
weeks (14 versus 18 in the CBT versus TAU groups respectively), both with a 
standard deviation of 6 and 90% power, 48 people would be needed in each group to 
provide data on the RAID at the primary end point (15 weeks). 
 
Discussion 
Summary of results 
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This trial demonstrated that formulation-based cognitive behavioural therapy (CBT) is 
feasible for people with mild to moderate dementia and clinically significant anxiety. 
At 15 weeks, there were differences in anxiety which approached significance, and 
these improvements remained at six months. Although the CBT intervention was 
targeted at the thoughts, feelings and behaviours characteristic of anxiety, the more 
significant finding was the difference in depression as measured by the CSDD at both 
15 and 26 week follow-up. CBT led to a short-term reduction in health and social care 
costs (by 15 weeks), although this reduction was not enough to outweigh the cost of 
the intervention itself. In other words, CBT was cost-neutral. There were no 
significant changes in any other outcomes.  
 
Acceptability and feasibility of CBT 
The therapy was acceptable to people with dementia and their family carers as 
demonstrated by their willingness to participate, uptake of the intervention and low 
level of withdrawal from the intervention. The intervention was feasible for those 
with mild to moderate dementia (MMSE scores ranging from 25 to 16), although 
greater scaffolding by the therapist, a slower pace, greater repetition, increased 
emphasis on behavioural rather than cognitive techniques and a higher degree of 
involvement from family carers was necessary with people in the more moderate 
stages of dementia. Participants with dementia who were able to identify (a) unhelpful 
persistent negative automatic thoughts, conditional beliefs (‘rules for living’) or self-
defeating cognitive processes (e.g. catastrophic thinking) and (b) more helpful 
alternative approaches, were also able to retain information and demonstrate the 
ability to ‘Stop, think and do differently’ without necessarily needing prompts from 
family carers. In cases where the person was unable to engage in such processes, 
family carers who had engaged with the CBT rationale were able to support the 
person to apply coping statements and techniques such as distraction and relaxation. 
A challenge for this research was creating a manualised approach with enough built in 
flexibility to cover a variety of clinical presentations, both in terms of the profile of 
cognitive deficits and the nature and duration of the anxiety. One method for 
providing flexibility is to have a range of ‘modules’ within the manual, an approach 
used both here and in the ‘Peaceful Mind’ CBT studies in the US [11,12].  
 
Strengths and limitations  
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There were several limitations to this study. Firstly, there was a significant difference 
in baseline anxiety on the RAID, with the TAU group being significantly more 
anxious. It is therefore hard to know how effective CBT might have been for a more 
anxious group and one would hope for a more balanced sample in a larger trial. One 
therapist saw the majority of patients (18 cases), with only four cases seen by the 
three other therapists (one of whom treated two cases and two who treated one case 
each). This could imply that the effects were largely due to the therapist rather than 
the intervention. However, the strength of this approach is that there was limited 
therapist variability, hence interpretations of the manual will have predominantly been 
the same. 
 
There was no measureable impact of the therapy on anxiety measured using the 
HADS. This may be due to the differences in content between the RAID and the 
HADS anxiety scale, or due to the differences in methods of administration. Both the 
CSDD and the RAID take into account the carer’s and rater’s view of presenting 
symptomatology rather than relying on self-report by the person with dementia alone.  
Finally, in a full trial we could do a full cost-effectiveness analysis, looking at trade-
offs between better outcomes and higher costs. This was not feasible with this small 
sample pilot, which only considered costs from a health and social care perspective. It 
may be hypothesised, for example, that CBT might lead to reduced carer costs if 
outcomes are better for the people with dementia. Our analysis of costs from an HSC 
perspective was a strength in that it is of relevance to decision-makers considering 
whether their organisation should implement CBT. 
 
Implications for research and practice 
The results suggest that a larger, fully powered RCT is now required to assess the 
effectiveness of CBT for anxiety in dementia. The data from this trial have been used 
to provide a power calculation for a full RCT, suggesting that a minimum of 96 
participants (48 in each group) would be required prior to inflation for drop out and 
additional inflation using the intra-class correlation associated with clustering by 
therapist. The manual is written for use by therapists who already have a good 
knowledge of using CBT and experience of work with people with dementia, 
although prior experience of carrying out CBT with people with dementia was not 
required.  Future research may be required in evaluating the effectiveness of the 
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therapy delivered by non-specialists. The manual developed for this trial will be 
published, enabling others to use it.  
 
Conclusion  
This pilot trial demonstrates that a full RCT of CBT for anxiety in people with 
dementia is feasible and that the manualised intervention is acceptable to people with 
dementia and their carers.  The results of this feasibility trial also suggest that the 
intervention leads to reductions in anxiety, depression and potentially short-term costs 
of other HSC services, although we are conscious that the result for anxiety lost 
statistical significance after adjustment for baseline values.  Our results on depression 
indicate further investigation of the effectiveness of CBT for depression in dementia 
is also warranted.  
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Statistical appendix 
We checked the distribution of all outcome measures.  Some of these were skew; 
hence medians (interquartile range) and means (standard deviation) are presented in 
Table 1.  After linear regression, we checked the assumption of normality of the 
residuals for each model by plotting them on a histogram.  Some were Normally 
distributed, despite the outcome variable not being Normal.  Where the residuals were 
deviant from Normal, we transformed the outcome using the most appropriate 
transformation to make the outcome Normally distributed (or very close to Normal) 
and then repeated the linear regression.  For some outcomes there was not a 
transformation that made the outcome near Normal. Where this was the case, we did 
not attempt to fit a model with a transformed outcome.  Where transformation 
occurred, the models with the transformed and untransformed outcomes were 
compared using Akaike Information Criteria (AIC). In the majority of cases, the 
models with the untransformed outcome were the best using this criterion. For others, 
there was little difference between them so we have presented results from the 
untransformed models in Tables 2 and 3. 
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Table 1: Baseline summary statistics for the participant by randomised group 
Variable CBT and TAU TAU 
Socio demographics Mean or n/N (SD) or % Mean or n/N (SD) or 
% 
Age 78 (7) 79 (7) 
Male 10/25 40 10/25 40 
Non-white ethnicity 0/25 0 1/25 4 
Years in education, median (IQR) 9 (9, 10) 10 (9, 11) 
Use of Anxiolytic medication 
(Lorezapam, Diazepam, Buspirone) 
Use of Antidepressant medication 
(Citalopram, Mirtazapine, Sertraline, 
Hydrochloride, Paroxetine, Venlafaxine, 
Amitriptyline) 
Use of Antipsychotic medication 
(Quetiapine, Seroquel) 
2/25 
 
12/25 
 
 
 
0/25 
8 
 
48 
 
 
 
0 
6/25 
 
9/25 
 
 
 
2/25 
24 
 
36 
 
 
 
8 
     
Standardised scales     
Participant     
MMSE median (IQR) 23 (19, 24) 23 (16, 25) 
MMSE mean (SD) 21 (5) 20 (6) 
QOL AD median (IQR) 35 (30, 38) 34 (32, 38)) 
QOL AD mean (SD) 34 (5) 35 (6) 
QCPR median (IQR) 61 (57, 63) 61 (56, 65) 
QCPR mean (SD) 59 (5) 60 (6) 
HADS total median (IQR) 12 (9, 18) 14 (9, 23) 
HADS total mean (SD) 14 (7) 16 (9) 
HADS Anxiety median (IQR) 7 (5, 12) 8 (6, 11) 
HADS Anxiety mean (SD) 8 (4) 9 (5) 
HADS Depression median (IQR) 5 (4, 6) 6 (3, 12) 
HADS Depression mean (SD) 5 (3) 7 (4) 
RAID median (IQR) 17 (14, 21) 22 (17, 24) 
RAID mean (SD) 18 (6) 21 (6) 
CSDD median (IQR) 13 (11, 17) 19 (13, 22) 
CSDD mean (SD) 14 (5) 18 (7) 
NPI total median (IQR) 22 (13, 31) 27 (22, 39) 
NPI total mean (SD) 24 (17) 28 (12) 
NPI total carer distress median (IQR) 10 (7, 16) 13 (9, 18) 
NPI total carer distress mean (SD) 12 (7) 14 (6) 
     
CDR questionable/mild dementia 21/25 84 21/25 84 
CDR moderate dementia 4/25 16 4/25 16 
Abbreviations: RAID Rating anxiety in dementia; MMSE Mini mental state examination; QOL 
AD Quality of life Alzheimer’s Disease; QCPR Quality of Caregiver-Patient Relationship; 
HADS Hospital Anxiety and Depression Scale; CSDD Cornell Scale for Depression in 
Dementia; NPI Neuropsychiatric Inventory; CDR Clinical Dementia Rating 
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Table 2: Baseline summary statistics for the carer by randomised group 
Variable CBT and TAU TAU 
 Mean or n/N (SD) or % Mean or n/N (SD) or 
% 
Socio demographics     
Age, median (IQR) 69 (62, 80) 66 (51, 74) 
Male 11/25 44 9/25 36 
Non-white ethnicity 0/25 0 0/25 0 
     
Relationship to participant     
Spouse/ partner 18/25 72 11/25 44 
Son/ daughter 7/25 28 9/25 36 
Other 0/25 0 5/25 20 
     
Time spent as a carer (months), 
median (IQR) 
24 (18, 48) 24 (18, 36) 
Hours a week spent caring, median 
(IQR) 
61 (10, 168) 15 (6, 80) 
     
QOL AD median (IQR) 33 (31, 35) 32 (27, 37) 
QOL AD mean (SD) 32 (5) 32 (6) 
QCPR total median (IQR) 57 (54, 61) 52 (48, 61) 
QCPR total mean (SD) 57 (7) 54 (8) 
HADS total median (IQR) 9 (4, 12) 9 (6, 13) 
HADS total mean (SD) 10 (6) 9 (5) 
HADS Anxiety median (IQR) 6 (2, 8) 5 (3, 9) 
HADS Anxiety mean (SD) 6 (4) 6 (4) 
HADS Depression median (IQR) 3 (1, 7) 4 (2, 4) 
HADS Depression mean (SD) 4 (4) 4 (2) 
Abbreviations: QOL AD Quality of life Alzheimer’s Disease; QCPR Quality of Caregiver-
Patient Relationship; HADS Hospital Anxiety and Depression Scale;  
 
23 
 
Table 3: Outcomes at 15 weeks and 6 months, coefficients for CBT 
Outcome Unadjusted Adjusted* Outcome Unadjusted Adjusted*   
Participant Coefficient 95% CI Participant Coefficient 95% CI Coefficient 95% CI Coefficient 95% CI 
RAID -4.32      (-8.21, -0.43) RAID -5.47 (-10.67, -
0.27) 
-4.59 (-9.34, 0.15) -3.10 (-6.55, 0.34) 
MMSE 1.45 (-2.58, 5.49) MMSE 0.86 (-2.75, 4.48) -0.06 (-1.94, 1.81) 0.21 (-1.72, 2.15) 
QOL AD 1.44 (-2.24, 5.12) QOL AD -0.85 (-4.49, 2.79) -0.90 (-4.52, 2.71) 0.70 (-2.85, 4.26) 
QCPR total 0.49 (-3.53, 4.50) QCPR total -2.53 (-6.86, 1.81) -2.81 (-7.15, 1.52) 0.58 (-3.64, 4.80) 
HADS total -0.75 (-5.09, 3.59) HADS total -0.05 (-5.60, 5.50) 0.22 (-4.88, 5.31) 0.02 (-3.89, 3.94) 
HADS Anxiety 0.47 (-1.89, 2.83) HADS 
Anxiety 
0.30 (-2.75, 3.35) 0.43 (-2.35, 3.21) 0.90 (-1.10, 2.90) 
HADS Depression -1.22 (-3.96, 1.52) HADS 
Depression 
-0.35 (-3.56, 2.86) -0.22 (-3.33, 2.90) -0.88 (-3.63, 1.88) 
CSDD -6.34 (-10.60, -2.08) CSDD -5.46 (-9.62, -1.31) -5.08 (-9.25, -0.92) -5.37 (-9.50, -1.25) 
NPI total -7.90 (-18.43, 2.63) NPI total -10.06 (-20.63, 0.51) -9.42 (-20.10, 1.27) -7.19 (-18.21, 3.82) 
NPI total carer distress -2.37 (-6.81, 2.06) NPI total 
carer distress 
-3.25 (-8.41, 1.91) -2.85 (-8.06, 2.36) -2.61 (-7.18, 1.97) 
          
Carer   Carer       
QOL AD 2.61 (-1.52, 6.74) QOL AD 2.41 (-1.88, 6.69) 1.08 (-1.81, 3.97) 1.00 (-1.85, 3.85) 
QCPR total 3.88 (-2.08, 9.85) QCPR total 5.24 (-0.39, 10.87) 1.27 (-2.38, 4.92) -0.32 (-4.88, 4.24) 
HADS total -0.60 (-4.27, 3.06) HADS total 0.25 (-3.78, 4.27) 0.93 (-2.06, 3.91) 0.07 (-2.62, 2.76) 
HADS Anxiety -0.80 (-3.34, 1.74) HADS 
Anxiety 
0.06 (-2.68, 2.79) 0.70 (-1.60, 2.99) -0.28 (-2.01, 1.44) 
HADS Depression 0.20 (-1.50, 1.90) HADS 
Depression 
0.19 (-2.11, 2.49) 0.16 (-1.64, 1.96) 0.38 (-0.92, 1.67) 
Abbreviations: RAID Rating anxiety in dementia; MMSE Mini mental state examination; QOL AD Quality of life Alzheimer’s Disease; QCPR Quality of 
Caregiver-Patient Relationship; HADS Hospital Anxiety and Depression Scale; CSDD Cornell Scale for Depression in Dementia; NPI Neuropsychiatric 
Inventory; CDR Clinical Dementia Rating 
 
*Participant outcomes control for baseline MMSE and baseline RAID.  Carer outcomes control for the outcome at baseline. 
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Table 4: Participant pre-baseline costs (£) by service group with mean imputations  
 CBT (N=25) 
 
TAU (N=25) 
 
Difference (unadjusted) 
 
Service group Mean SD Mean SD  Mean 95% bias-
corrected CI 
Accommodation 492.77 2349.54 - - 492.77 (20.05, 1706.41) 
Hospital services  614.32 742.16 558.10 961.47 56.22 (-435.97, 499.06) 
Community 
services 
744.66 1458.53 565.47 715.84 179.19 (-311.87, 997.75) 
Equipment/ 
adaptations 
26.13 62.33 29.59 92.07 -3.47 (-54.12, 35.33) 
Day-services 88.79 217.52 44.52 135.72 44.28 (-52.80, 146.21) 
Medication 296.98 193.85 231.70 162.26 65.28 (-31.04, 175.57) 
Total (Health and  
social care 
perspective) 
2263.65 3937.53 1429.38 1342.21 834.27 (-285.77, 3069.38) 
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Table 5: Participant costs (£) between baseline and first follow-up (15 weeks) by service group with mean imputations  
 CBT (N=21) 
 
TAU (N=18) 
 
Difference (unadjusted) 
 
Difference (adjusted*) 
 
Service group Mean SD Mean SD Mean 95% bias-
corrected CI 
Mean 95% bias-corrected 
CI 
Accommodation 17.85 81.79 48.58 206.12 -30.74 (-140.22, 78.75) -4.88 (-96.86, 61.03) 
Hospital 
services  
244.10 277.36 460.17 526.09 -216.07 (-510.82, 36.41) -146.34 (-446.93, 55.91) 
Community 
services 
321.60 427.14 767.40 930.73 -445.80 (-978.57, -2.00) -417.19 (-980.13, -95.35) 
Equipment/ 
adaptations 
20.94 76.73 32.30 90.14 -11.37 (-64.85, 36.68) -11.84 (-78.66, 42.95) 
Day-services 111.53 332.36 70.30 152.85 41.23 (-80.77, 250.47) 20.15 (-90.11, 223.48) 
Medication 266.55 170.47 283.85 176.08 -17.3 (-128.48, 90.49) -4.27 (-115.26, 106.71) 
Total (Health 
and 
 social care 
perspective) 
982.56 823.55 1662.61 1170.58 -680.04 (-1401.91, -67.46) -564.38 (-1252.08, -112.85) 
CBT 
intervention 
cost 
1002.01 222.65 - - 1002.01 (892.01, 1086.42) 1010.96 (898.46, 1102.99) 
Health and 
social care  
plus CBT cost 
1984.58 841.02 1662.61 1170.58 321.97 (-345.94, 946.85) 769.80 (-121.99, 1697.38) 
*Adjusted for baseline HSC costs, baseline MMSE and baseline RAID. 
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Table 6: Participant costs (£) between first follow-up (15 weeks) and second follow-up (6 months) by service group with mean imputations 
 
 CBT (N=21) 
 
TAU (N=17) 
 
Difference (unadjusted) 
 
Difference (adjusted*) 
 
Service group Mean SD Mean SD  Mean 95% bias-
corrected CI 
Mean 95% bias-
corrected CI 
Accommodation 113.63 520.73 - - 113.63 (76.98, 280.74) 19.08 (-94.02, 129.03) 
Hospital 
services  
448.84 650.05 296.68 345.75 152.16 (-152.81, 493.88) 79.05 (-175.83, 334.93) 
Community 
services 
1396.37 4067.95 623.30 832.37 773.07 (-401.88, 3117.64) 85.67 (-627.76, 1102.29) 
Equipment/ 
adaptations 
2.34 6.51 3.80 7.66 -1.47 (-5.74, 3.38) -2.25 (-6.42, 2.03) 
Day-services 84.99 144.45 61.29 84.25 23.70 (-44.42, 105.85) 16.37 (-55.33, 95.59) 
Medication 297.56 179.77 273.65 160.45 23.91 (-92.28, 129.09) 58.20 (-36.01, 151.23) 
Total (Health 
and  
social care 
perspective) 
2343.73 5072.26 1258.72 971.47 1085.02 (-354.81, 4078.64) 256.12 (-599.05, 1506.23) 
*Adjusted for baseline HSC costs, baseline MMSE and baseline RAID. 
 
 
 
Figure 1: CONSORT Diagram 
 
 
  
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
Participants interviewed at 
Baseline  N = 50 
 
Excluded N = 103  
 
Eligibility criteria not met        N = 63 
 
Refused Participation         N = 34 
 
PwD ill health             N = 2 
 
PwD has passed away          N = 4 
1
st
 follow-up assessment 
(15 weeks post 1st 
randomisation) 
 
Completed N = 39 
(TAU = 18, CBT = 21) 
Not assessed 2
nd
 follow-up  
N = 0 
 
 
2nd follow-up assessment 
(6 months post 1
st
 
randomisation) 
Completed  N = 38 
Overdue / booked N = 0 
Due / booked  N = 0 
 
(TAU = 17, CBT = 21) 
Referrals (by source) N = 153 
Secondary Care  N = 93 
Voluntary Sector  N = 22 
Other research studies N = 7 
Psychiatrists’ Clinic   N=26 
Letters   
Other   N = 5 
Randomised  
N = 50 
TAU = 25, CBT = 25 
 
Informed consent 
recorded  N = 50 
Lost by 1
st
 follow-up   N = 6 
 
Withdrawals:  
- Dissatisfaction about receiving  
  TAU  N = 2 
- Carer stressors        N = 2 
- FC feels participation is too    
  Stressful for PwD            N = 1 
- Unobtainable N = 1 
CBT - Lost at 2
nd
 follow-up N = 1 
 
- PwD declined to continue after 3    
  sessions of therapy and declined 
not the first, but only the second 
follow up assessment    N = 1 
CBT - Not assessed 1
st
 follow-up  
 
- Hosp. admission of PwD     N = 1 
 
Key 
CMHT = Community mental 
health team 
PwD = Person with dementia 
FC = Family carer 
 
TAU  
N = 19 
CBT  
N = 22 
Lost by 1
st
 follow-up   N = 3 
 
Withdrawals before 1
st
 session: 
- FC felt CBT not needed  N = 1 
- PwD withdrew N = 1 
  
Other: 
- PwD passed away            N = 1 
 
Recruitment sources (number of organisations/doctors):  
Secondary NHS services (CMHT, Memory Clinics, Cognitive Disorder Clinics, Day Centres, Outpatient Clinics, 
Psychotherapy services, Hospitals)         N = 16 
Voluntary organisations (Age Concern, Cross Roads, Alzheimer’s Society)    N = 23 
Social Services            N = 1 
Screening of doctors’ case notes and letters        N = 2 
Referrals (by source) N = 50 
Secondary Care N = 38 
Voluntary Sector N = 5 
Clinic Letters  N = 7 
TAU - Not assessed 1
st
 follow-up 
 
- Unable to contact        N = 1 
 
TAU - Lost at 2
nd
 follow-up N = 2 
 
- PwD ill health, later died     N = 1 
- PwD living in care        N = 1 
